Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology

哺乳动物中的组氨酸磷酸化:调节、蛋白质靶点和生物学

基本信息

项目摘要

Project Summary Whereas phosphorylation of serine, threonine and tyrosine are exceedingly well characterized, relatively little is known about phosphorylation of histidine (His), which may account for as much as ~6% of all incorporation of phosphate into mammalian proteins. We have provided genetic and biochemical evidence that the histidine kinase, NDPK-B, and the histidine phosphatases (PTases), PHPT1 and (PGAM5, regulate the activity of the Ca2+-activated K+ channel KCa3.1 by reversible His phosphorylation, and thereby the activation of CD4 T and mast cells. While NDPK-B His phosphorylates and activates KCa3.1, PGAM5 and PHPT1 inhibit KCa3.1 His phosphorylation by specifically dephosphorylating and inhibiting NDPK-B and KCa3.1 respectively. Using recently developed monoclonal antibodies to 1- and 3-phospho-Histidine (pHis), we demonstrate for the first time the regulation of histidine phosphorylation in vivo in mammalian cells, which we in turn linked to TCR signaling. SA1 we will build on these studies, we will assess changes in His phosphorylation of NDPK-B and KCa3.1 in the context of TCR signaling, determine how it is regulated by various signaling molecules such as PI3KC2, whether other pHis proteins are present in T cells and/or regulated by TCR signaling, and the specific role for PGAM5, PHPT1 and NDPK-B to modulate changes in pHis proteins. We have found that the 24 cleaved PGAM5-L isoform is most critical to dephosphorylate NDPK-B. We will determine whether the 24 cleaved PGAM5-L isoform negatively regulates CD4 T cells in vivo, whether the amount of this isoform changes following TCR stimulation, and the intramembranous proteases that mediates cleavage in CD4 T cells. We also identified a critical role for histidine phosphorylation in pancreatic  cell function. We found that  cells from PHPT1-/- mice have electrical properties similar to those of patients with mutations in KATP channel subunits and KATP channel-/- mice. The defect in PHPT1-/- β cells can be explained by the failure of KATP channels to relocalize from an intracellular compartment to the plasma membrane (PM) in response to low glucose and leptin and we have now linked the defect in PHPT1-/- β cells to impaired activation of transient receptor potential channel 4 (TRPC4). Our hypothesis is that reversible His phosphorylation of TRPC4 by PHPT1, NDPK-B, PGAM5 regulates TRPC4 channel activity in a similar manner to KCa3.1, albeit in opposite directions; whereas His phosphorylation of KCa3.1 activates, His phosphorylation of TRPC4 inhibits. In SA 2, we will determine if PHPT1, NDPK-B, and PGAM5 regulate His phosphorylation of TRPC4 in a manner similar to KCa3.1, their role in KATP channel trafficking and TRPC4 activation, and whether decreased KATP trafficking to the PM in TRPC4-/- and PGAM5-/- mice leads congenital hyperinsulinemia hypoglycemia that is similar to PHPT-/- mice and patients with CHI. We will then extend these studies to human  cells and assess the potential relevance of these molecules to human disease that include CHI and type 2 diabetes mellitus.
项目摘要 丝氨酸,苏氨酸和酪氨酸的磷酸化更为完全,相对 关于组氨酸(HIS)的磷酸化知之甚少,这可能占所有收入的约6% 磷酸盐成哺乳动物蛋白。我们提供了组氨酸的遗传和生化证据 激酶,NDPK-B和组氨酸磷酸酶(PTases),PHPT1和(PGAM5)调节 Ca2+激活的K+通道KCA3.1通过可逆他的磷酸化,从而激活CD4 T和 肥大细胞。而NDPK-B他的磷酸化并激活KCA3.1,PGAM5和PHPT1抑制KCA3.1他 分别通过特异性去磷酸化和抑制NDPK-B和KCA3.1的磷酸化。使用 最近开发了对1和3-磷酸 - 抗二氨酸(PHIS)的单克隆抗体,我们首次证明 在哺乳动物细胞中体内组氨酸磷酸化的调节,我们又与TCR信号传导有关。 SA1我们将基于这些研究,我们将评估他在NDPK-B和KCA3.1磷酸化中的变化 TCR信号的上下文,确定如何通过各种信号分子(例如PI3KC2)调节其 其他Phis蛋白存在于T细胞中,//或受TCR信号的调节,PGAM5的特定作用, PHPT1和NDPK-B调节PHIS蛋白的变化。我们发现24裂解PGAM5-L 同工型对于去磷酸化的NDPK-B最重要。我们将确定24是否裂解PGAM5-L 同工型在体内负调节CD4 T细胞,该同工型的量是否在TCR后发生变化 刺激以及介导CD4 T细胞裂解的膜内蛋白酶。 我们还确定了组氨酸磷酸化在胰腺细胞功能中的关键作用。我们发现 来自PHPT1 - / - 小鼠的细胞具有与KATP通道突变患者相似的电特性 亚基和KATP通道 - / - 小鼠。 PHPT1 - / - β细胞中的缺陷可以通过KATP通道的失败来解释 从葡萄糖和低葡萄糖和 Leptin,我们现在将PHPT1 - / - β细胞中的缺陷与瞬时受体电位的激活相关联 频道4(TRPC4)。我们的假设是,由PHPT1,NDPK-B,NDPK-B,NDPK-B的磷酸化可逆 PGAM5以与KCA3.1相似的方式调节TRPC4通道活性,尽管朝相反的方向调节。然而 他的KCA3.1磷酸化激活,他的TRPC4磷酸化抑制。在SA 2中,我们将确定是否 PHPT1,NDPK-B和PGAM5以类似于KCA3.1的方式调节TRPC4的磷酸化 在KATP渠道贩运和TRPC4激活中,以及在Trpc4中的KATP贩运降低到PM PGAM5 - / - 小鼠牵引先天性高胰岛素血症低血糖,与PHPT - / - 小鼠和患者相似 与Chi。然后,我们将将这些研究扩展到人类细胞,并评估这些研究的潜在相关性 包括CHI和2型糖尿病的人类疾病分子。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD Y SKOLNIK其他文献

EDWARD Y SKOLNIK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD Y SKOLNIK', 18)}}的其他基金

Identification of new therapeutic targets for ADPKD
ADPKD 新治疗靶点的确定
  • 批准号:
    10462701
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Identification of new therapeutic targets for ADPKD
ADPKD 新治疗靶点的确定
  • 批准号:
    10629396
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Identification of new therapeutic targets for ADPKD
ADPKD 新治疗靶点的确定
  • 批准号:
    10298937
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology
哺乳动物中的组氨酸磷酸化:调节、蛋白质靶点和生物学
  • 批准号:
    10395477
  • 财政年份:
    2019
  • 资助金额:
    $ 39.83万
  • 项目类别:
Identification and characterization of a novel mammalian histidine phosphatase that negatively regulates CD4 T cells
负调节 CD4 T 细胞的新型哺乳动物组氨酸磷酸酶的鉴定和表征
  • 批准号:
    9330534
  • 财政年份:
    2016
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8667953
  • 财政年份:
    2013
  • 资助金额:
    $ 39.83万
  • 项目类别:
New Signaling pathways that positively and negatively regulate CD4 T cells via th
通过 th 正向和负向调节 CD4 T 细胞的新信号通路
  • 批准号:
    8742789
  • 财政年份:
    2013
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8541082
  • 财政年份:
    2012
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8218480
  • 财政年份:
    2012
  • 资助金额:
    $ 39.83万
  • 项目类别:
TRIM27 is a new negative regulator of CD4 T cells and Mast cells.
TRIM27 是 CD4 T 细胞和肥大细胞的新型负调节因子。
  • 批准号:
    8875012
  • 财政年份:
    2012
  • 资助金额:
    $ 39.83万
  • 项目类别:

相似国自然基金

MyD88介导树突状细胞分泌TNF调控EAE发生机制研究
  • 批准号:
    82371350
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
索拉非尼通过诱导调节性T细胞抑制自身免疫性疾病的研究
  • 批准号:
    32370955
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
自身免疫性疾病相关因子VGLL3调控DNA损伤应答与肿瘤免疫微环境重塑研究
  • 批准号:
    82341006
  • 批准年份:
    2023
  • 资助金额:
    150 万元
  • 项目类别:
    专项基金项目
自身免疫性疾病精准诊疗中基于非编码RNA组学和生物信息学的新方法研究
  • 批准号:
    82371855
  • 批准年份:
    2023
  • 资助金额:
    74 万元
  • 项目类别:
    面上项目
核苷酸转移酶cGAS乙酰化修饰抑制剂的设计、合成及抗自身免疫性疾病的机制研究
  • 批准号:
    82273767
  • 批准年份:
    2022
  • 资助金额:
    51 万元
  • 项目类别:
    面上项目

相似海外基金

Targeting fibrosis to change cancer outcomes
针对纤维化改变癌症结果
  • 批准号:
    10748730
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
Host and microbe-dependent mechanisms of enhanced autoimmune susceptibility driven by checkpoint inhibitors
检查点抑制剂驱动的增强自身免疫易感性的宿主和微生物依赖性机制
  • 批准号:
    10750805
  • 财政年份:
    2023
  • 资助金额:
    $ 39.83万
  • 项目类别:
BIOPHYSICAL TUNING OF CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING FOR SAFE AND EFFECTIVE T CELL IMMUNOTHERAPY
嵌合抗原受体 (CAR) 信号转导的生物物理调节以实现安全有效的 T 细胞免疫治疗
  • 批准号:
    10413245
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
BIOPHYSICAL TUNING OF CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING FOR SAFE AND EFFECTIVE T CELL IMMUNOTHERAPY
嵌合抗原受体 (CAR) 信号转导的生物物理调节以实现安全有效的 T 细胞免疫治疗
  • 批准号:
    10284715
  • 财政年份:
    2021
  • 资助金额:
    $ 39.83万
  • 项目类别:
Mechanisms of B cell specific IL-35 expression in cancer.
癌症中 B 细胞特异性 IL-35 表达的机制。
  • 批准号:
    9910621
  • 财政年份:
    2020
  • 资助金额:
    $ 39.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了